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Summary 14 
Background: Whilst cobalt is an essential micronutrient for vitamin B12 synthesis in the horse, at 15 
supra-physiological concentrations it has been shown to enhance performance in humans and rats 16 
and there is evidence that its administration in high doses to horses poses a welfare threat.  Animal 17 
sport regulators currently control cobalt abuse via international race day thresholds, but since cobalt 18 
may be present in physiological concentrations this work was initiated to explore means of potentially 19 
adding to application of those thresholds.  20 
Objectives: To devise a scientific basis for differentiation between presence of cobalt from bona fide 21 
supplementation and cobalt doping through the use of ratios.    22 
Study design: Six Thoroughbred horses were given 10 ml vitamin B12/cobalt supplement (Hemo-23 
15®a, 1.5 mg B12, 7 mg cobalt gluconate = 983 µg total Co) as an intravenous bolus then an 24 
intravenous infusion (15 minute) of 100 mg cobalt chloride (45.39 mg Co) six weeks later.  Pre-and 25 
post-administration plasma and urine samples were analysed for cobalt and vitamin B12.   26 
Methods: Urine and plasma samples were analysed for vitamin B12 using an immunoassay and 27 
cobalt concentrations were measured via ICP-MS. Baseline concentrations of cobalt in urine and 28 
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plasma for each horse were subtracted from their cobalt concentrations post administration for the PK 29 
analysis. Compartmental analysis was used for the determination of plasma PK parameters for cobalt 30 
using commercially available software. 31 
Results: On administration of a vitamin B12/cobalt supplement, the ratio of cobalt to vitamin B12 in 32 
plasma rapidly increased to approximately three and then rapidly declined below a ratio of one and 33 
then back to near baseline over the next week. On administration of 100 mg cobalt chloride the ratio 34 
initially exceeded ten in plasma and then declined with the lower 95% confidence interval remaining 35 
above a ratio of one for seven days. For two horses with extended sampling the plasma ratio 36 
remained above one for approximately 28 days after cobalt chloride administration. 37 
The effect of the administration of the vitamin B12/cobalt supplement on the urine ratio was transient 38 
and reached a peak value of ten which then rapidly declined. However, a urine ratio of ten was 39 
exceeded, with the lower 95% confidence interval remaining above a ratio of ten for seven days after 40 
cobalt chloride administration. For the two horses with extended sampling, the urine ratio remained 41 
above ten for about 18 days (442 hours) after cobalt chloride administration even though the absolute 42 
cobalt urine concentration had dropped below the international threshold of 100 ng/ml after 96 hours. 43 
Main limitations: Only one vitamin B12/cobalt product was evaluated, a limited number of horses 44 
were included, the horses were not in full race training and the results may be specific to this 45 
population of horses.  46 
Conclusions:  The results provide the basis for a potential strategy for allowing supplementation with 47 
vitamin B12 products whilst controlling the misuse of high doses of cobalt, through a combination of 48 
international thresholds and ratios of cobalt to vitamin B12, in plasma and urine. 49 
 50 
 51 
Introduction 52 
Cobalt is an essential micronutrient needed for vitamin B12 synthesis in the equine caecum and colon. 53 
Under normal circumstances, adult horses obtain sufficient cobalt from their diet to meet their daily 54 
demand and supplemental cyanocobalamin, a synthetic form of vitamin B12, is only beneficial if there 55 
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is vitamin B12 deficiency [1] manifesting as weakness and megaloblastic anaemia [2].  Such 56 
supplements are currently permitted in horses in training.  There is evidence that supra-physiological 57 
concentrations of cobalt enhance performance in humans and rats by protecting muscle groups 58 
against oxidative stress and stabilising HIF2α, subsequently increasing erythropoiesis and therefore 59 
aerobic capacity and athletic performance [3,4]. However, cobalt compromises equine welfare at high 60 
doses [5], and there is a need to regulate it in racehorses.  61 
 62 
Global surveys of urine and plasma cobalt concentrations in racehorse populations have led to the 63 
agreement of race day cobalt thresholds of 100 ng/mL (urine) and 25 ng/mL (plasma) by the 64 
International Federation of Horseracing Authorities (IFHA). This has been complemented by 65 
collaborative pharmacokinetic (PK) studies involving cobalt containing products [6,7].  Many of the 66 
studies have involved single administrations and there are limited data with regard to multiple dosing 67 
regimens of cobalt supplements which may result in cobalt accumulation.  Cobalt supplements for 68 
intravenous administration usually comprise cyanocobalamin, containing approximately 4% cobalt in 69 
the trivalent state Co (III), and inorganic cobalt in the divalent state (II); both must be considered.  If 70 
cobalt, included with preparations also containing vitamin B12, is regularly supplemented in the horse’s 71 
diet, it is hypothesised that as well as cobalt increasing in the circulation, increased vitamin B12 72 
concentrations will be observed as a marker of administration. A ratio approach to cobalt versus 73 
vitamin B12 in conjunction with total cobalt ‘dose’ may help distinguish a horse receiving vitamin B12 74 
supplementation from one administered inorganic cobalt salts, enabling horseracing authorities to 75 
regulate the abuse of inorganic cobalt whilst allowing bona fide supplementation with cobalt containing 76 
products.  The aims of the study were therefore, (i) To analyse plasma and urine samples for vitamin B12 77 
and cobalt before and after the administration of a vitamin B12/cobalt supplement then cobalt chloride to 78 
six horses, determining excretion profiles, and (ii) to establish whether the administration of a vitamin 79 
B12/cobalt supplement can be distinguished from administration of cobalt chloride by comparing the 80 
post-administration ratios of vitamin B12 and cobalt. 81 
 82 
Materials and Methods 83 
Horse Phase 84 
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Six Thoroughbred horses (five geldings and one filly aged 4-10 years and weighing 490-542 kg) fed a 85 
normal racehorse diet and housed at the British Horseracing Authority’s Centre for Racehorse Studies 86 
(Newmarket, UK) were used for this study.  They were exercised daily according to a programme 87 
typical of a training yard to include sessions on the horse walker, trot and canter work over varying 88 
distances depending on the individual horse and their level of fitness. Control blood and urine 89 
samples were taken on each of five consecutive days in the week preceding administration on Day 1.  90 
Each ‘blood sample’ comprised 4 x 10 ml lithium heparin vacutainers being filled with venous blood. 91 
The vacutainers were centrifuged and plasma harvested and frozen at nominally -20°C immediately 92 
after collection.  Each urine sample comprised 165 ml urine taken from the total voided by free flow at 93 
each time point. 94 
On Day 1, an intravenous catheter (Milacath®b) was placed into the left jugular vein of each horse.  A 95 
sixth control blood sample was taken via the catheter immediately prior to 10 ml of a vitamin 96 
B12/cobalt supplement (Hemo-15®a) (stated by manufacturer to contain 1.5 mg B12, 7 mg cobalt 97 
gluconate = 983 µg cobalt) being administered intravenously into the contralateral jugular vein at 9 98 
am.  Blood samples were collected via the catheter at 15, 30, 60, 90, 120, 180, 240, 300, 360, 420, 99 
540, 660, 780, 900, 1020, 1140, 1260, 1380, 1500, 1620, 1740 and 1860 minutes post dose 100 
(Supplementary Item 1). Urine samples voided through the day were collected from the time of dosing 101 
until 900 hours post dose.  On Day 2, one urine sample was collected as close to 09.00 h and then 102 
17.00 h as possible. On Day 3, one blood sample was taken via the catheter at 09.00 h and one at 103 
17.00 h then catheters removed.  One urine sample was collected as close to 09.00 h and 17.00 h as 104 
possible.  On Days 4, 5, 6, 8, 15, 22, 29 and 36, one blood sample was taken by venepuncture each 105 
morning at 09.00 h with one urine sample taken each day as close to this time as possible. 106 
On Day 43, 6 weeks after the administration of the vitamin B12/cobalt supplement, an intravenous 107 
catheter was again placed into the left jugular vein of each horse.  A control blood sample was taken 108 
via the catheter immediately prior to intravenous infusion of 100 mg cobalt chloride (45.39 mg cobaltc  109 
in 250 ml normal saline (400 µg/ml cobalt) over 15 minutes.  Blood samples were collected via the 110 
catheter at 15, 30, 60, 90, 120, 180, 240, 300, 360, 420, 540, 660, 780, 900, 1020, 1140, 1260, 1380, 111 
1500, 1620, 1740 and 1860 minutes post dose. Urine samples voided through the day were collected 112 
up until 900 minutes post dose.  On Day 44, one urine sample was collected as close as possible to 113 
09.00 h and then 17.00 h.  On Day 45, one blood sample was taken via the catheter at 09.00 h and 114 
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one at 17.00 h before the catheters were removed and one urine sample was collected in the morning 115 
and one in the afternoon, again as close as possible to 09.00 h and 17.00 h respectively. One blood 116 
and one urine sample were collected on Days 46, 48 and 50, with just urine on the intervening days 117 
until Day 51.  Collection of blood and urine was extended by a further three weeks, with twice weekly 118 
sampling for the fifth and sixth horses in the study owing to refinement of the study protocol from data 119 
produced in the first horses. 120 
 121 
Laboratory Analysis 122 
All samples were analysed at LGC (Newmarket, UK).  Ultra-pure water was provided by a water 123 
system (Ultra Clear Duod). The Immulite® vitamin B12 assay kit included components of the working 124 
solution, sample diluent, substrate solution, probe wash concentrate and Immulite® sample cupse.  125 
Elemental stocks were provided at 1,000 ppm (1 mg/ml) from Romilf and VHG Laboratoriesg. 126 
Solutions of nitric acid (HNO3) at 3.4% and 0.68% were prepared from a Super Purity Acid grade (67-127 
69%) concentrated solution (Romilf). All consumables were plastic. 128 
Vitamin B12 analysis (urine and plasma) 129 
The analysis of all urine and plasma samples for vitamin B12 was carried out using a clinical analyser 130 
(Immulite® 1000e), according to the protocol provided with the assay kit.  Before starting sample 131 
analysis, the protocol required the analysis of adjuster solutions to be within criteria set by the 132 
manufacturer. The purpose of the adjustment was to align the internal instrument calibration with the 133 
master curve for each kit lot number which was generated by the manufacturer; eliminating the 134 
requirement to process standard curves during each batch of samples. The adjusters were also run 135 
as quality control (QC) samples at the beginning and end of each analytical batch to monitor the 136 
performance of the assay. 137 
Pre- and post-administration urine and plasma samples were defrosted overnight at nominally 4°C 138 
prior to analysis.  For each experimental batch, a working solution was prepared by combining 1,000 139 
μL borate-potassium cyanide buffer with 20 μL dithiothreitol per sample, and was scaled up as 140 
appropriate.  A volume (1,000 μL) of working solution was added to 200 μL dilute sample (diluted with 141 
Immulite® sample diluent). The typical starting dilution for both the urine and plasma samples was 1:5; 142 
however, some samples were found to be outside of the assay concentration range (150 – 1200 143 
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pg/mL) so required re-testing at an alternative dilution factor. The range of dilutions required for 144 
analysis of urine samples was between 1:2 and 1:800, whilst the plasma samples were diluted 145 
between 1:5 and 1:40.  146 
The sample was boiled at 100°C for 15 minutes to inactivate vitamin B12-binding proteins, before 147 
being incubated in a room-temperature water bath for a further five minutes. A portion of the prepared 148 
sample was aliquoted into a sample cup, which was placed on the instrument for analysis followed by 149 
a vitamin B12 test unit. The remainder of the assay was fully automated with the raw data generated 150 
by the Immulite® 1000 being in the form of a print-out indicating the concentration of vitamin B12 in 151 
each sample, measured in pg/mL.  152 
Elemental analysis (including cobalt): urine 153 
Pre- and post-administration urine samples were defrosted overnight at nominally 4°C prior to 154 
analysis. An aliquot from each was centrifuged for 15 min at 1,500 g.  For each experimental batch, a 155 
series of calibration samples was prepared in HNO3 (3.4%) containing 12 elemental analytes at 156 
concentrations of 0.0, 0.1, 0.5, 1.0, 5.0, 10 and 50 ng/mL; bromine and magnesium were spiked at 157 
0.0, 1.0, 5.0, 10, 50, 100 and 500 ng/mL. A QC sample was independently prepared containing 5 158 
ng/mL of each element (50 ng/mL bromine and magnesium) in the dilute acid.  159 
Additionally, positive control samples were prepared in duplicate: 10 mL of pooled control equine 160 
urine was spiked at the respective cobalt and arsenic concentrations of 100 and 300 ng/mL; a volume 161 
(1 mL) of this was then diluted 50-fold in 3.4% HNO3. These positive control samples were analysed 162 
throughout each experimental batch to demonstrate that matrix components were not adversely 163 
affecting the assay. Two further aliquots (200 µL) of the same urine pool were prepared for analysis 164 
(un-spiked) by 50-fold dilution into 3.4% HNO3. These samples permitted adjustment of the positive 165 
control results for the endogenous urinary concentrations of the two spiked analytes.  A volume (200 166 
µL) of the relevant administration urine samples were diluted 50-fold in 3.4% HNO3.  An internal 167 
standard solution (bismuth, germanium and indium) in 3.4% HNO3 was added to each calibration, QC, 168 
positive control, un-spiked matrix and administration sample at a final concentration of 10 ng/mL.  169 
Finally, samples enabling calculation of the instrumental limit of detection and lower limit of 170 
quantification were analysed (in sextuplicate) alongside each batch, consisting of 10 ng/mL internal 171 
standard mix in 3.4% HNO3.  The assay of all urine samples was carried out using a 7500ce ICP-MS 172 
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operating with ChemStation G1834B software version B.04.00h, coupled with a Cetac ASX-520 173 
autosampleri. 174 
 175 
A radio frequency power of 1550 W was employed. The argon carrier gas flow rate was set at 1.06 176 
L/min and the spray chamber temperature was set at 2°C. Helium (3.2 mL/min) was used as the 177 
collision gas. The peristaltic pump speed was set at 0.1 revolutions per second during analysis. After 178 
each injection, the autosampler probe was rinsed with 0.68% HNO3 (v/v) for 30 s in the rinse port and 179 
washed before each new set of samples in 3.4% HNO3 (v/v) for 40 s to minimise contamination from 180 
carry over. Data acquisitions were performed in spectrum analysis (multi tune) mode. 181 
Elemental analysis (including cobalt): plasma 182 
Administration plasma samples were defrosted overnight at nominally 4°C prior to analysis.  For every 183 
batch, calibration samples were prepared in HNO3 (0.68%) containing 12 elemental analytes at 184 
concentrations of 0.0, 0.1, 0.5, 1.0, 5.0, 10 and 20 ng/mL; bromine and magnesium were spiked at 185 
0.0, 1.0, 5.0, 10, 50, 100 and 200 ng/mL. A QC sample was independently prepared containing 5 186 
ng/mL of each element (50 ng/mL bromine and magnesium) in the acid solution. 187 
Analogous to urine, duplicated plasma positive control samples were prepared: 2 mL of pooled control 188 
equine plasma was spiked at the respective cobalt and arsenic concentrations of 25 and 75 ng/mL; a 189 
volume (1 mL) of this was then diluted 50-fold in 0.68% HNO3. Two further aliquots (200 µL) of the 190 
plasma pool were diluted (un-spiked) by 50-fold into 0.68% HNO3 allowing background concentrations 191 
of cobalt and arsenic to be accounted for.  Preparation of QC and limit of detection/lower limit of 192 
quantification assessment samples, in addition to that of the administration plasma samples 193 
themselves, was performed as described for urine but using 0.68% HNO3.  Internal standard solution 194 
in 0.68% HNO3 was added to each sample at a final concentration of 10 ng/mL.  The assay of plasma 195 
samples was performed as for urine. 196 
Pharmacokinetic Analysis 197 
Baseline concentrations of cobalt (average of pre-administration samples) in urine and plasma for 198 
each horse were subtracted from their cobalt concentrations post administration for the 199 
pharmacokinetic (PK) analysis. Compartmental analysis was used for the determination of plasma 200 
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pharmacokinetic parameters for cobalt using commercially available software (Phoenix WinNonlin 201 
Version 6.0j). A compartmental model was chosen based on the coefficient of variation, Akaike 202 
Information Criterion and visual inspection of the residual plots.  The area under the curve for cobalt 203 
concentration in urine was calculated using the trapezoidal method via a non-compartmental analysis 204 
(NCA) using the same software. The ratio of cobalt to vitamin B12 was determined by dividing the 205 
measured concentration of cobalt in ng/mL by the measured concentration of vitamin B12 in ng/mL i.e. 206 
baseline concentrations were not subtracted as the ratio is meant to represent what would be 207 
expected from a sample taken on race day or while the horse is in training. The 95% confidence 208 
interval was generated for the ratios using GraphPad Prism version 7.00 for Windowsk. 209 
Results 210 
Following urine elemental analysis, all acid QCs were found to be within ± 10% for cobalt in terms of 211 
both intra-batch precision (coefficient of variation, CV) and relative error (RE). All cobalt positive 212 
control samples demonstrated intra-batch CV measurements within 10% and fell within the calculated 213 
99% confidence interval (± 11%). Across eight batches, the mean cobalt limit of detection was 214 
calculated to be 0.44 ng/mL (in undiluted urine) whilst the calculated lower limit of quantification was 215 
not greater than the bottom calibration sample (equivalent to 5 ng/mL in undiluted urine). 216 
 217 
During plasma elemental analysis, all acid QCs were within ± 10% for cobalt in terms of both intra-218 
batch precision (CV) and RE. Cobalt positive control samples revealed intra-batch CV and RE 219 
measurements within 10% and ± 15%, respectively. The mean cobalt limit of detection over 13 220 
analytical batches was 0.57 ng/mL (in undiluted plasma) and the calculated lower limit of 221 
quantification did not exceed the bottom calibration sample (equivalent to 5 ng/mL in undiluted 222 
plasma). 223 
 224 
Figure 1 displays the mean plasma and urine total cobalt concentration for the single administration of 225 
a vitamin B12/cobalt supplement (983 µg Co) followed by cobalt chloride administration (45.39 mg) at 226 
time equals zero and 1008 hours, respectively. Plasma and urine cobalt physiological baseline levels 227 
(pre-administration) were approximately 1 and 2 ng/mL, respectively. There was an increase in cobalt 228 
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concentration in both plasma and urine after the vitamin B12/cobalt supplement, more detail of which 229 
is seen in the expanded view in Supplementary Item 2. Supplementary Item 2 displays the plasma 230 
and urine total cobalt concentrations for the first 24 hours after the single administration of a vitamin 231 
B12/cobalt supplement. Plasma and urine cobalt concentrations returned to near baseline levels 232 
approximately 672 hours after the vitamin B12/cobalt supplement administration compared with 233 
approximately 1176 hours for the cobalt chloride administration.  234 
Plasma cobalt levels dropped below the 25 ng/mL plasma threshold within 2 hours post administration 235 
and by 4 hours it was below 10 ng/mL in all horses whereas urine cobalt concentrations peaked 236 
above the threshold of 100 ng/mL at about 2 hours with all horses’ concentrations below it by 8 hours 237 
post administration. After returning to near baseline levels cobalt concentrations in urine and plasma 238 
remained unchanged until the administration of cobalt chloride (Fig 1).   239 
Baseline concentrations of cobalt (pre-administration samples) for each horse were subtracted from 240 
their cobalt concentrations post administration of the vitamin B12/cobalt supplement and the resulting 241 
data set, up to the administration of cobalt chloride, was analysed using compartmental analysis. 242 
Based on coefficient of variation, Akaike Information Criterion and visual inspection of the residual 243 
plots, a three-compartment bolus model (Supplementary Item 3) with a weighting factor of 1/ŷ gave 244 
the best fit to the cobalt concentration data points from individual animals. Table 1 displays the PK 245 
parameters using a 3-compartmental model which gave a low mean clearance of 0.028 mL/min/Kg 246 
and a moderate steady-state volume of distribution (Vss) of 0.635 L/Kg. The terminal (Gamma) 247 
plasma half-life was very long with a geometrical mean value of 319 hours. 248 
Supplementary Item 4 displays the plasma and urine total cobalt concentration for the single 249 
administration of cobalt chloride (45.39 mg Co) for the first 21 days after administration. Cobalt 250 
chloride administration caused a sharp increase in cobalt concentration in both plasma and urine, and 251 
peaked at maximums of 700 ng/ml and 20 µg/ml, respectively.  Urine cobalt concentrations were 252 
higher than plasma for the first 24 hours after administration but then fell below the plasma 253 
concentrations at 72-96 hours with the rate of decline being much faster in urine, and urine 254 
concentrations thereafter were lower than plasma.  The two horses sampled for longer showed cobalt 255 
plasma concentrations flattening at 1344 hours post administration of cobalt chloride but did not quite 256 
return to baseline at the point where sampling stopped (Fig 1).   257 
   10 
 
Baseline concentrations of cobalt (pre-administration samples) were subtracted from cobalt 258 
concentrations post administration of cobalt chloride and the resulting data set was analysed using 259 
compartmental analysis. Based on coefficient of variation, Akaike Information Criterion and visual 260 
inspection of the residual plots, a three-compartment infusion model with a weighting factor of 1/ŷ 261 
gave the best fit to the cobalt concentration data points from individual animals. Table 2 displays the 262 
PK parameters using a 3-compartmental model which gave a low mean clearance of 0.07 mL/min/Kg 263 
and a moderate steady-state volume of distribution (Vss) of 0.711 L/Kg. The terminal (Gamma) 264 
plasma half-life was long with a geometrical mean value of 132 hours.  265 
The average concentration, based upon a once a day vitamin B12/cobalt supplement regimen, from 266 
first dose to steady-state is expected to increase by 8.3 and 1.8 fold for plasma and urine, 267 
respectively (Table 3). The extent of accumulation is expected to be slightly less for the once a day 268 
administration of cobalt chloride where the average cobalt concentration is expected to increase by 269 
5.5 and 1.3 fold once steady-state has been reached for plasma and urine, respectively (Table 3). 270 
Figure 2 shows that both plasma and urine concentrations of vitamin B12 peaked then decreased after 271 
administration of the vitamin B12/cobalt supplement but at a slower rate of decrease than the cobalt 272 
(Supplementary Item 2).  As shown in Supplementary Item 5, an expanded view of the first 168 hours 273 
after administration, vitamin B12 concentrations reverted to baseline in plasma within eight hours and 274 
urine concentrations fell to background concentrations of approximately 1 ng/ml within 72 hours.  275 
Supplementary Item 6 shows, as would be expected, that administration of cobalt chloride had no 276 
effect on plasma or urine B12 concentrations.  Supplementary Items 7 and 8 show the individual horse 277 
data used to calculate the average plasma and urine concentrations of, respectively, cobalt and 278 
vitamin B12 in Supplementary Items 2, 4, 5 and 6.     279 
Based upon background levels within these horses there was approximately ten times more vitamin 280 
B12 than cobalt in plasma when using units of ng/mL (Fig 3a). On administration of a vitamin B12/cobalt 281 
supplement, the ratio of cobalt to vitamin B12 rapidly increased to approximately 3 owing to the relative 282 
quantities of cobalt gluconate to vitamin B12 in the product and then rapidly declined below a ratio of 1 283 
and then back to near baseline over the next week. On administration of 100 mg cobalt chloride, 284 
because only cobalt and not vitamin B12 was given, the ratio initially exceeded ten in plasma and then 285 
declined with the lower 95% confidence interval remaining above a ratio of 1 for 7 days. For the two 286 
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horses with extended sampling the ratio remained above 1 for approximately 28 days after cobalt 287 
chloride administration (Fig 3a). 288 
Based upon background levels within these horses there was approximately 1-2 times more cobalt 289 
than vitamin B12 in urine (Fig 3b).  As in plasma, the effect of the administration of the vitamin 290 
B12/cobalt supplement on the urine ratio was transient and reached a peak value of 10 which then 291 
rapidly declined. However, a urine ratio of 10 was exceeded, with the lower 95% confidence interval 292 
remaining above a ratio of 10 for 7 days after cobalt chloride administration. For the two horses with 293 
extended sampling the urine ratio remained above 10 for about 18 days (442 hours) after cobalt 294 
chloride administration even though the absolute cobalt urine concentration had dropped below the 295 
threshold of 100 ng/ml after 96 hours. 296 
 297 
Discussion 298 
The PK parameters obtained following cobalt chloride administration in the current study are 299 
consistent with those obtained in a previous study by Knych et al. [6] that investigated the PK of a 300 
single administration of cobalt chloride (49 mg Co; Table 2). In the previous study, cobalt chloride was 301 
infused i.v. over a 10-minute period and in this situation it is imperative that PK samples are taken 302 
during the infusion period. Based upon the alpha half-life found previously [6] it was estimated that a 303 
reasonable back extrapolation for the PK parameter, V1, would be obtained from a first sample point 304 
taken 15 minutes post bolus administration so as to reduce the number of blood samples taken. The 305 
mean clearance value obtained by Knych et al. [6] was slightly higher than found in the current CoCl2 306 
study which would not be the case if the early portion of the AUC was missed. In both the current and 307 
previous studies, cobalt chloride clearance and terminal half-life parameters (Table 2) are larger (3 x) 308 
and shorter (2 x), respectively, compared with the parameters obtained for the lower cobalt ‘dose’ 309 
present in the vitamin B12/cobalt preparation administration (Table 1). The higher clearance value for 310 
the single administration of cobalt chloride (49 mg Co) relative to the administration of the vitamin 311 
B12/cobalt preparation used in the current study may be due to a reduction in cobalt re-absorption 312 
from the kidney back to blood.  The dose used for the vitamin B12/cobalt preparation was the 313 
recommended dose of this product, licensed for use in many countries. The single dose of cobalt 314 
chloride was representative of a ‘doping’ dose that could affect performance and have adverse side 315 
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effects. This ‘doping’ dose was based upon doses in human which have shown increases in EPO and 316 
was the same as the dose used in the Knych (2012) study. The pharmacokinetic argument put 317 
forward is that there is only one possible explanation for the clearance to be higher for the higher 318 
dose cobalt chloride administration relative to the vitamin B12/cobalt preparation i.e. the reabsorption 319 
mechanism from urine to blood is saturated for high concentrations of cobalt in the urine but for lower 320 
doses (and lower urine levels) reabsorption returns to first order kinetics. 321 
 322 
In plasma, the threshold of 25 ng/ml is only exceeded for a couple of hours after the administration of 323 
the current vitamin B12/cobalt preparation whereas urine concentrations drop below the 100 ng/mL 324 
threshold by approximately 8 hours. Based upon the predicted accumulation (Table 3) it would be 325 
highly unlikely that any increase in urine concentration would exceed a 100 ng/mL urine screening 326 
limit with a once a day regimen of the current vitamin B12/cobalt preparation or equivalent dose cobalt 327 
supplement. However, based on a Monte Carlo simulation (data not shown), the 25 ng/mL plasma 328 
threshold could potentially be breached in a population of horses with a once a day regimen of a 329 
vitamin B12/cobalt supplement or equivalent dose cobalt supplement. Therefore, practitioners should 330 
continue to advise caution when using these products in racehorses. 331 
Following administration of cobalt chloride alone the plasma threshold of 25 ng/ml was exceeded for 332 
at least 7 days and in the 2 horses with extended sampling, up to 15 days (360 hours) post 333 
administration, whereas urine concentrations drop below the 100 ng/mL threshold by approximately 334 
120 hours (5 days).  335 
Although the total cobalt concentration was above 25 ng/mL in plasma for at least 7 days after a 100 336 
mg cobalt chloride administration, the use of a cobalt to vitamin B12 ratio may potentially extend the 337 
period of detection for this doping practice and allow regulators to differentiate it from administration of 338 
a typical cobalt/vitamin B12 supplement with total cobalt dose of approximately 1mg, such as the 339 
vitamin B12/cobalt supplement in this study. The current study demonstrated that cobalt originating from 340 
the administration of a product containing cobalt and vitamin B12 could be distinguished from cobalt 341 
originating from the administration of exclusively inorganic cobalt salts by the differences in the ratio of 342 
cobalt to vitamin B12 associated with each, in both plasma and urine. There were a number of 343 
limitations of the study which included; only one vitamin B12/cobalt product was evaluated, however a 344 
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number of commercial B12 products are available with variable cobalt content; only a single dose was 345 
administered and multiple doses are required to confirm the estimated extent of accumulation; only 346 
six horses were investigated, which were not in full race training and therefore the results may be 347 
specific to this population of horses.  348 
A strategy for allowing supplementation with cobalt/vitamin B12 containing products whilst controlling 349 
the misuse of high doses of inorganic cobalt could be based on using a combination of such a ratio of 350 
cobalt to vitamin B12, in plasma and urine with the existing IFHA thresholds for cobalt of 100 ng/ml in 351 
urine and 25 ng/ml in plasma.  Such a strategy, summarised in Table 4, would require two phases; i.e. 352 
control within 24 hours of an administration, which would cover a race day, and control for longer than 353 
24 hours from administration in the case of training surveillance. 354 
It should be noted that the pharmacokinetics of cobalt resulting from the administration of legitimate 355 
cobalt/B12 supplements, such as the vitamin B12/cobalt supplement used here, suggest that 356 
accumulation of cobalt in plasma as a result of multiple daily administrations may exceed the 357 
international threshold of 25 ng/mL within a population of horses. Therefore, more studies are required 358 
that investigate the extent of accumulation in plasma resulting from a multi-dose regimen of cobalt 359 
supplements. No significant accumulation of cobalt concentration is expected within urine.     360 
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Figure legends: 396 
Fig 1: Average (6 horses) plasma (red) and urine (green) cobalt concentrations (± s.d. for n>2 397 
common time points) during the sequential administrations of a vitamin B12/cobalt preparation (t = 0 398 
hours) and cobalt chloride (t = 1008 hours), with IFHA adopted thresholds of 25 and 100 ng/mL 399 
respectively 400 
 401 
Fig 2: Average (6 horses) plasma (red) and urine (green) vitamin B12 concentrations (± s.d. for n>2 402 
common time points) during the sequential administrations of a vitamin B12/cobalt preparation (t = 0 403 
hours) and cobalt chloride (t = 1008 hours) 404 
 405 
Fig 3a and 3b: Average (6 horses) plasma (red) and urine (green) ratio of cobalt to vitamin B12 406 
concentrations (95% CI for n>2 common time points) during the sequential administrations of a 407 
vitamin B12/cobalt preparation (t = 0 hours) and cobalt chloride (t = 1008 hours).  408 
 409 
 410 
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Tables 431 
 432 
Table 1: Pharmacokinetic parameters of cobalt following a single intravenous administration of a 433 
vitamin B12/cobalt preparation (983 µg Co) to 6 exercised Thoroughbred horses using a 3-434 
compartment bolus PK model. See Supplementary Item 3 for parameter definitions. 435 
 436 
Horse Weight 
(Kg) 
V1 
(L/Kg) 
V2 
(L/Kg) 
V3 
(L/Kg) 
Alpha HL 
(h) 
Beta HL 
(h) 
Gamma HL 
(h) 
MRT 
(h) 
Vss 
(L/Kg) 
CL 
(mL/min/kg) 
1 504 0.0692 0.105 0.363 1.14 14.5 245 307 0.537 0.029 
2 542 0.126 0.175 0.562 0.810 13.7 432 585 0.863 0.025 
3 508 0.0094 0.0734 0.453 0.731 25.8 231 223 0.536 0.040 
4 532 0.088 0.140 0.213 1.28 67.6 463 530 0.441 0.014 
5 498 0.128 0.130 0.511 0.981 12.9 348 463 0.768 0.028 
6 490 0.127 0.123 0.415 1.00 13.2 266 349 0.666 0.032 
Mean 512 0.0912 0.124 0.419 0.973* 19.7* 319* 410 0.635 0.028 
Median 506 0.107 0.126 0.434 0.992 14.1 307 406 0.601 0.028 
*Geometric mean 437 
  438 
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 439 
Table 2: Pharmacokinetic parameters of cobalt following a single intravenous administration of 45.39 440 
mg cobalt as cobalt chloride to 6 exercised Thoroughbred horses using a 3-compartment infusion PK 441 
model. See Supplementary Item 3 for parameter definitions.  442 
 443 
Horse Weight 
(Kg) 
V1 
(L/Kg) 
V2 
(L/Kg) 
V3 
(L/Kg) 
Alpha HL 
(hrs) 
Beta HL 
(hrs) 
Gamma HL 
(hrs) 
MRT 
(hrs) 
Vss 
(L/Kg) 
CL 
(mL/min/kg) 
1 504 0.214 0.248 0.302 1.41 14.3 100 126 0.764 0.100 
2 542 0.188 0.165 0.367 1.41 12.0 150 195 0.720 0.061 
3 508 0.168 0.0119 0.358 0.0671 0.629 97.2 138 0.538 0.065 
4 532 0.156 0.141 0.544 0.567 5.79 122 159 0.840 0.088 
5 498 0.149 0.311 0.335 1.61 24.3 182 230 0.795 0.058 
6 490 0.0152 0.199 0.393 0.0364 8.99 166 212 0.608 0.048 
Mean 512 0.148 0.180 0.383 0.405* 7.18* 132* 177 0.711 0.070 
a 494-626 0.130 0.162 0.639 0.434* 6.80* 149* 200 0.940 0.083 
Median 506 0.162 0.182 0.362 0.988 10.5 136 177 0.741 0.063 
b 494-626 0.132 0.156 0.630 0.660 6.31 143 184 0.924 0.084 
 444 
*Geometric mean; a,bKnych et al. (2015) mean and median data 445 
 446 
  447 
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Table 3: Average ± s.d. estimated ratio of the area under the curve (AUC) in the first 24 hours relative 448 
to the total AUC extrapolated to infinity and the predicted accumulation of the average cobalt 449 
concentration upon administration every 24 hours until steady-state has been reached. 450 
 451 
Administration Matrix AUC0-24/AUC 0-inf  ± s.d. Accumulation (SS) ± s.d. 
vitamin B12/cobalt 
preparation Plasma 0.153 ± 0.100 8.28 ± 3.43 
 Urine 0.615 ± 0.209 1.84 ± 0.78 
Cobalt Chloride Plasma 0.186 ± 0.031 5.48 ± 0.82 
 Urine 0.778 ± 0.075 1.30 ± 0.12 
 452 
  453 
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Table 4: Anticipated testing outcomes relating to scenarios involving the administration of a vitamin 454 
B12/cobalt product or cobalt chloride relative to the international cobalt thresholds and cobalt to 455 
vitamin B12 ratios (h or d is the hours or days a positive result persists based upon the average horse 456 
concentration or ratio). 457 
Cobalt 
Administration 
Time Period 
(hours) 
Plasma Threshold  
(>25 ng/mL) 
Urine 
Threshold 
(>100 ng/mL) 
Plasma Co/B12 
Ratio > 1 
Urine Co/B12 
Ratio > 10 
Routine use of 
a vitamin 
B12/cobalt 
preparation 
<24 positive (2 h) positive (8 h) positive positive 
>24 negative negative negative negative 
Doping with 
Cobalt Chloride 
(100 mg dose) 
<24 positive positive positive positive 
>24 positive (15 d) positive (4 d) positive (15 d) positive (18 d) 
 458 
  459 
